Milan - Delayed Quote EUR

Regeneron Pharmaceuticals, Inc. (1REGN.MI)

510.80

-24.40

(-4.56%)

At close: May 5 at 11:25:09 AM GMT+2

Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y

ALNY reports better-than-expected first-quarter results as both earnings and revenues beat estimates, driven by higher product sales.

Zacks 4 days ago

ALNY

REGN
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Arguably The Most Innovative Biopharma Company I’ve Seen In The Last Two Decades’

We recently published an article titled Jim Cramer Listed 20 Best Performing Stocks of the Last 20 Years. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks. Discussing two decades of Mad Money, Jim Cramer took a moment to highlight the top-performing stocks since […]

Insider Monkey 4 days ago

REGN

RGEN
Regeneron Pharmaceuticals (NasdaqGS:REGN) To Showcase Oncology And Respiratory Data At Major Conferences

Regeneron Pharmaceuticals (NasdaqGS:REGN) is poised for an eventful month, highlighting exciting advancements in their cancer and respiratory disease treatments at upcoming conferences. Following a week where the broader market witnessed a 2.7% rise, Regeneron’s stock nudged up 1.86%. Although the company’s announcements regarding its oncology and hematology findings, in addition to the European approval for Lynozyfic™, could generate interest, the market’s overall positive momentum, partly...

Simply Wall St. 5 days ago

REGN
Regeneron price target lowered to $940 from $975 at Truist

Truist lowered the firm’s price target on Regeneron (REGN) to $940 from $975 but keeps a Buy rating on the shares. The firm is reducing its expected Eylea sales given the company’s near-term outlook, though while near-term investor focus remains on the Eylea tail, Regeneron continues to deliver growth on top/bottom line in the near to longer-term with Dupi and Libtayo, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time, market-moving bre

TipRanks 5 days ago

REGN
Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination

18 presentations across five cancer types include new insights on the potential of checkpoint inhibitors and bispecific antibodiesTARRYTOWN, N.Y., May 01, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data from its oncology and hematology portfolio will be shared at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 to June 3 in Chicago, IL. Eighteen presentations will share the latest insights

GlobeNewswire 5 days ago

REGN
Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases

24 abstracts, including 1 oral presentation and 4 late-breaking posters on Dupixent, to showcase new clinical and real-world analyses in chronic obstructive pulmonary disease (COPD) and asthma COPD data from the landmark Phase 3 trials will highlight Dupixent impact on lung function and health-related quality of life across broad populations of patients with type 2 inflammation Asthma abstracts include late-breaking data on mucus burden and the first presentation of efficacy results from a Phase

GlobeNewswire 5 days ago

REGN
Company News for Apr 30, 2025

Companies In The News Are: NUE, REGN, PYPL, PFE.

Zacks 6 days ago

NUE

PFE

REGN
Regeneron Pharmaceuticals First Quarter 2025 Earnings: Revenues Disappoint

Regeneron Pharmaceuticals ( NASDAQ:REGN ) First Quarter 2025 Results Key Financial Results Revenue: US$3.03b (down 3.7...

Simply Wall St. 6 days ago

REGN
Regeneron Pharmaceuticals Inc (REGN) Q1 2025 Earnings Call Highlights: Strong Dupixent Sales ...

Regeneron Pharmaceuticals Inc (REGN) reports robust growth in Dupixent sales and strategic R&D investments, while navigating EYLEA sales decline and regulatory hurdles.

GuruFocus.com 6 days ago

REGN
Q1 2025 Regeneron Pharmaceuticals Inc Earnings Call

Q1 2025 Regeneron Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents 6 days ago

REGN
Regeneron Crashes 7% After Eylea Miss Drags Its Earnings Down

Regeneron stock tumbled Tuesday after the biotech giant reported a major revenue miss due to light sales of its eye drug Eylea.

Investor's Business Daily 6 days ago

REGN
Equity Markets Higher Despite Weak US Consumer Confidence Data

US benchmark equity indexes are on track to close higher on Tuesday, despite April's US consumer con

PREMIUM
MT Newswires 6 days ago

SBAC

REGN
Regeneron Pharma Margins Tighten As Competition Grows, Stock Slides

On Tuesday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported first-quarter adjusted earnings per share of $8.22, down 14% year-over-year, missing the consensus of $8.82. The company reported sales of $3.03 billion, down 4%, missing the consensus of $3.29 billion. In the first quarter, U.S. net sales for Eylea HD and Eylea decreased 26% year-over-year to $1.04 billion, including $307 million from Eylea HD. Also Read: FDA Sets The Countdown: Regeneron’s Eylea HD Could Be Headed For Major Expan

Benzinga 7 days ago

REGN
Why Regeneron (REGN) Stock Is Falling Today

Shares of biotech company Regeneron (NASDAQ:REGN) fell 9.6% in the morning session after the company reported weak first-quarter 2025 results. Its revenue missed significantly, and its EPS fell short of Wall Street's estimates. Revenue declined 4% from the prior year, as Regeneron struggled to offset the double-digit decline in net product sales, including a 29% plunge in legacy EYLEA, despite a 54% jump in EYLEA HD. Overall, this quarter could have been better.

StockStory 7 days ago

REGN
Regeneron Pharmaceuticals Stock Sinks as Eylea Q1 Sales Trail Estimates

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported first-quarter sales—especially those of its key Eylea eye disease drug—that missed analysts' estimates by a wide margin.

Investopedia 7 days ago

REGN

^GSPC
Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down

REGN reports lower-than-expected Q1 results. Lead drug Eylea sales plunge in the United States due to competition. Stock down.

Zacks 7 days ago

REGN

SNY

BAYN.DE
Top Stock Movers Now: Honeywell, Sherwin-Williams, Regeneron, and More

Major U.S. stock indexes were higher at midday as markets awaited more information about potential White House tariff deals.

Investopedia 7 days ago

SHW

HON

REGN
Regeneron Stock Plummets After Earnings Miss

First-quarter adjusted earnings per share were $8.22 on revenue of $3 billion, missing analysts’ expectations.

Barrons.com 7 days ago

REGN
Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say

The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks 7 days ago

REGN
Regeneron's first-quarter results miss on lower Eylea demand

(Reuters) -Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking investor worries as U.S. regulators denied approval for a more convenient version of the eye therapy. Shares of Regeneron were down nearly 8%. Regeneron has been looking to switch patients to a higher-dose version of the drug, branded as Eylea HD, to stymie the loss in market share to cheaper versions and rivals.

Reuters 7 days ago

REGN

SNY

Performance Overview

Return	1REGN.MI	S&P 500 (^GSPC)
YTD	-25.22%	-4.36%
1-Year	-40.77%	+8.58%
3-Year	-30.03%	+36.42%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Regeneron Pharmaceuticals, Inc. (1REGN.MI)

Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y

Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Arguably The Most Innovative Biopharma Company I’ve Seen In The Last Two Decades’

Regeneron Pharmaceuticals (NasdaqGS:REGN) To Showcase Oncology And Respiratory Data At Major Conferences

Regeneron price target lowered to $940 from $975 at Truist

Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination

Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases

Company News for Apr 30, 2025

Regeneron Pharmaceuticals First Quarter 2025 Earnings: Revenues Disappoint

Regeneron Pharmaceuticals Inc (REGN) Q1 2025 Earnings Call Highlights: Strong Dupixent Sales ...

Q1 2025 Regeneron Pharmaceuticals Inc Earnings Call

Regeneron Crashes 7% After Eylea Miss Drags Its Earnings Down

Equity Markets Higher Despite Weak US Consumer Confidence Data

Regeneron Pharma Margins Tighten As Competition Grows, Stock Slides

Why Regeneron (REGN) Stock Is Falling Today

Regeneron Pharmaceuticals Stock Sinks as Eylea Q1 Sales Trail Estimates

Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down

Top Stock Movers Now: Honeywell, Sherwin-Williams, Regeneron, and More

Regeneron Stock Plummets After Earnings Miss

Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say

Regeneron's first-quarter results miss on lower Eylea demand

Performance Overview